医疗系统人群中神经精神疾病相关拷贝数变异的识别
该队列研究在Geisinger医疗系统90 595名参与者中评估了31种神经精神疾病相关拷贝数变异(CNV)的患病率与外显率,并探讨披露结果的个人效用。708人(0.8%)检出致病性CNV,其神经精神疾病诊断编码比例(28.8% vs 13.3%)及抑郁焦虑史比例(66.4% vs 54.6%)均显著高于CNV阴性者,仅5.8%既往已知遗传诊断。结果支持将神经精神疾病纳入人群基因组筛查。
要点
- 90 595名参与者中708人(0.8%)检出致病性神经精神疾病相关CNV,其中仅5.8%既往已知遗传诊断。
- CNV阳性者神经精神疾病编码比例28.8%,显著高于CNV阴性者的13.3%(OR 2.21,95%CI 1.86-2.61,P<.001)。
- CNV阳性者抑郁焦虑史比例66.4%,显著高于CNV阴性者的54.6%(OR 1.53,95%CI 1.31-1.80,P<.001)。
核心结论
- 在医疗系统人群中检出致病性神经精神疾病相关CNV的比例为0.8%,且与神经精神疾病诊断及抑郁焦虑史显著相关。
- 研究结果支持将神经精神疾病相关CNV纳入未来人群基因组筛查设计,以促进临床有用基因组信息的公平可及。
研究设计与样本
- 队列研究,基于Geisinger MyCode社区健康倡议,纳入2007年2月至2017年4月招募的90 595名有外显子组和关联电子健康记录数据的参与者。
- 通过外显子组数据确定31种神经精神疾病相关CNV的频率,用关联电子健康记录评估相关临床表型。
- 由持证遗传咨询师选择9种CNV进行结果披露,采用混合方法评估参与者的心理社会反应。
主要发现
- 90 595名参与者中708人(0.8%)检出致病性CNV,其中436名女性(61.6%),平均年龄50.04岁(SD 18.74)。
- 708名CNV阳性者中494人(70%)至少有一种相关临床症状。
- CNV阳性者神经精神疾病编码比例28.8%(204人),CNV阴性者为13.3%(11 835/89 887),OR 2.21(95%CI 1.86-2.61,P<.001)。
- CNV阳性者抑郁焦虑史比例66.4%(470人),CNV阴性者为54.6%(49 118/89 887),OR 1.53(95%CI 1.31-1.80,P<.001)。
- 16p13.11(71人,0.078%)和22q11.2(108人,0.119%)分别为最常见的缺失和重复;仅5.8%(41/708)既往已知遗传诊断。
关键数值与推荐
- 共评估31种神经精神疾病相关CNV,其中9种被选为结果披露。
- 完成结果披露141人,部分参与者对获知终身认知和精神残疾的医学原因表现出强烈反应。
临床怎么用
- 在精神心理科临床中,对伴有认知或精神障碍且病因不明者,可考虑CNV检测以明确遗传诊断。
- 人群基因组筛查项目可考虑纳入神经精神疾病相关CNV,以识别高风险个体并提供遗传咨询。
- 披露CNV结果时需关注参与者的心理社会反应,提供充分支持。
局限性
- 研究基于单一美国综合医疗系统人群,结果外推需谨慎。
- 仅9种CNV被选为披露,心理社会反应评估样本限于141人。
- CNV阳性者中仅5.8%既往已知遗传诊断,提示临床识别不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Population screening for medically relevant genomic variants that cause diseases such as hereditary cancer and cardiovascular disorders is increasing to facilitate early disease detection or prevention. Neuropsychiatric disorders (NPDs) are common, complex disorders with clear genetic causes; yet, access to genetic diagnosis is limited. We explored whether inclusion of NPD in population-based genomic screening programs is warranted by assessing 3 key factors: prevalence, penetrance, and personal utility. OBJECTIVE: To evaluate the suitability of including pathogenic copy number variants (CNVs) associated with NPD in population screening by determining their prevalence and penetrance and exploring the personal utility of disclosing results. DESIGN, SETTING, AND PARTICIPANTS: In this cohort study, the frequency of 31 NPD CNVs was determined in patient-participants via exome data. Associated clinical phenotypes were assessed using linked electronic health records. Nine CNVs were selected for disclosure by licensed genetic counselors, and participants' psychosocial reactions were evaluated using a mixed-methods approach. A primarily adult population receiving medical care at Geisinger, a large integrated health care system in the United States with the only population-based genomic screening program approved for medically relevant results disclosure, was included. The cohort was identified from the Geisinger MyCode Community Health Initiative. Exome and linked electronic health record data were available for this cohort, which was recruited from February 2007 to April 2017. Data were collected for the qualitative analysis April 2017 through February 2018. Analysis began February 2018 and ended December 2019. MAIN OUTCOMES AND MEASURES: The planned outcomes of this study include (1) prevalence estimate of NPD-associated CNVs in an unselected health care system population; (2) penetrance estimate of NPD diagnoses in CNV-positive individuals; and (3) qualitative themes that describe participants' responses to receiving NPD-associated genomic results. RESULTS: Of 90 595 participants with CNV data, a pathogenic CNV was identified in 708 (0.8%; 436 women [61.6%]; mean [SD] age, 50.04 [18.74] years). Seventy percent (n = 494) had at least 1 associated clinical symptom. Of these, 28.8% (204) of CNV-positive individuals had an NPD code in their electronic health record, compared with 13.3% (11 835 of 89 887) of CNV-negative individuals (odds ratio, 2.21; 95% CI, 1.86-2.61; P < .001); 66.4% (470) of CNV-positive individuals had a history of depression and anxiety compared with 54.6% (49 118 of 89 887) of CNV-negative individuals (odds ratio, 1.53; 95% CI, 1.31-1.80; P < .001). 16p13.11 (71 [0.078%]) and 22q11.2 (108 [0.119%]) were the most prevalent deletions and duplications, respectively. Only 5.8% of individuals (41 of 708) had a previously known genetic diagnosis. Results disclosure was completed for 141 individuals. Positive participant responses included poignant reactions to learning a medical reason for lifelong cognitive and psychiatric disabilities. CONCLUSIONS AND RELEVANCE: This study informs critical factors central to the development of population-based genomic screening programs and supports the inclusion of NPD in future designs to promote equitable access to clinically useful genomic information.
引用
- Martin CL, Wain KE, Oetjens MT, et al. Identification of Neuropsychiatric Copy Number Variants in a Health Care System Population. JAMA Psychiatry. 2020. PMID: 32697297. doi:10.1001/jamapsychiatry.2020.2159
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。